Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research
International Journal of Molecular Sciences · 17.12.2024 · 25 (24) · 13518
DOI: 10.3390/ijms252413518 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.12.2024. Verfasst von Mariona Pont und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Group of Cancer Biomarkers, Biomedical Research Institute of Lleida (IRBLleida), Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III through the project P21/00438 and the Miguel Servet fellowship.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) represents roughly one-sixth of all breast cancer patients, but accounts for 30–40% of breast cancer deaths. Due to the lack of typical biomarkers exploited clinically for breast cancer, it remains very difficult to treat. Moreover, its intrinsic high heterogeneity and proneness to become resistant to the drugs administered makes the treatment management very challenging for oncologists. Herein, we outline the different therapies used currently for TNBC and list the ongoing clinical trials to provide an overview of the most recent TNBC therapeutic landscape. In addition, we highlight the emerging therapies in the preclinical stage that hold the most promise, such as epigenetic modulators, CRISPR, miniproteins, radioconjugates, cancer vaccines, and PROTACs. Moreover, we navigate through the existing limitations and challenges which hamper the development of new and more effective treatments for TNBC. Lastly, we point to emerging new directions that may revolutionize future therapy for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Group of Cancer Biomarkers, Biomedical Research Institute of Lleida (IRBLleida), Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain.
- Department of Medicine, University of Lleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain.
ORCID-Profile: Mariona Pont, Marta Marqués, Anabel Sorolla
Förderung
- Instituto de Salud Carlos III
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III through the project P21/00438 and the Miguel Servet fellowship
- European Regional Development Fund/European Social Fund
- Agency for Management of University and Research Grants of Catalonia
- CERCA Programme of Generalitat de Catalunya and the IRBLleida—Fundació Dr. Pifarré
Zitieren
APA
Pont, M., Marqués, M., & Sorolla, A. (2024). Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research. International Journal of Molecular Sciences, 25(24), 13518. https://doi.org/10.3390/ijms252413518
Vancouver
Pont M, Marqués M, Sorolla A. Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research. International Journal of Molecular Sciences. 2024;25(24):13518. doi:10.3390/ijms252413518
BibTeX
@article{Pont2024,
author = {Pont, Mariona and Marqués, Marta and Sorolla, Anabel},
title = {Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {24},
pages = {13518},
doi = {10.3390/ijms252413518}
}
EUVIMED